Structural and Functional Impairments of Reconstituted High-Density Lipoprotein by Incorporation of Recombinant β-Amyloid42
暂无分享,去创建一个
[1] In-Chul Lee,et al. Native High-Density Lipoproteins (HDL) with Higher Paraoxonase Exerts a Potent Antiviral Effect against SARS-CoV-2 (COVID-19), While Glycated HDL Lost the Antiviral Activity , 2021, Antioxidants.
[2] Ling Li,et al. The Role of HDL and HDL Mimetic Peptides as Potential Therapeutics for Alzheimer’s Disease , 2020, Biomolecules.
[3] S. Kanba,et al. Serum elaidic acid concentration and risk of dementia , 2019, Neurology.
[4] A. Sahebkar,et al. Emerging roles for high‐density lipoproteins in neurodegenerative disorders , 2019, BioFactors.
[5] V. Lowe,et al. Apolipoprotein A-I Crosses the Blood-Brain Barrier through Clathrin-Independent and Cholesterol-Mediated Endocytosis , 2019, The Journal of Pharmacology and Experimental Therapeutics.
[6] K. Cho. High-Density Lipoproteins as Biomarkers and Therapeutic Tools: Volume 2. Improvement and Enhancement of HDL and Clinical Applications , 2019 .
[7] M. Sarzynski,et al. Effects of exercise on HDL functionality , 2019, Current opinion in lipidology.
[8] M. Mimura,et al. The association between midlife serum high-density lipoprotein and mild cognitive impairment and dementia after 19 years of follow-up , 2019, Translational Psychiatry.
[9] C. E. Kosmas,et al. High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease , 2018, Drugs in context.
[10] Sunhee Choi,et al. Glycation of Lys-16 and Arg-5 in amyloid-β and the presence of Cu2+ play a major role in the oxidative stress mechanism of Alzheimer’s disease , 2017, JBIC Journal of Biological Inorganic Chemistry.
[11] M. V. van Boxtel,et al. Coronary heart disease and risk for cognitive impairment or dementia: Systematic review and meta-analysis , 2017, Alzheimer's & Dementia.
[12] Wai Hang Cheng,et al. Reconstituted high-density lipoproteins acutely reduce soluble brain Aβ levels in symptomatic APP/PS1 mice. , 2016, Biochimica et biophysica acta.
[13] N. Ferlazzo,et al. Citrus bergamia Juice Extract Attenuates β-Amyloid-Induced Pro-Inflammatory Activation of THP-1 Cells Through MAPK and AP-1 Pathways , 2016, Scientific Reports.
[14] C. Wellington,et al. HDL and cholesterol handling in the brain. , 2014, Cardiovascular research.
[15] Kyung-Hyun Cho,et al. Elaidic acid (EA) generates dysfunctional high-density lipoproteins and consumption of EA exacerbates hyperlipidemia and fatty liver change in zebrafish. , 2014, Molecular nutrition & food research.
[16] S. Lerakis,et al. High-Density Lipoprotein Functionality in Coronary Artery Disease , 2014, The American journal of the medical sciences.
[17] S. Lovestone,et al. Advanced glycation end products, dementia, and diabetes , 2014, Proceedings of the National Academy of Sciences.
[18] W. Song,et al. Molecular links between Alzheimer’s disease and diabetes mellitus , 2013, Neuroscience.
[19] A. Hakim,et al. Heart disease as a risk factor for dementia , 2013, Clinical epidemiology.
[20] S. Hama,et al. HDL functionality , 2012, Current opinion in lipidology.
[21] Yining Huang,et al. Nonenzymatic glycation of high‐density lipoprotein impairs its anti‐inflammatory effects in innate immunity , 2012, Diabetes/metabolism research and reviews.
[22] V. Demarin,et al. Low high-density lipoprotein cholesterol as the possible risk factor for stroke. , 2010, Acta clinica Croatica.
[23] Dong-gu Shin,et al. Senescence-related truncation and multimerization of apolipoprotein A-I in high-density lipoprotein with an elevated level of advanced glycated end products and cholesteryl ester transfer activity. , 2010, The journals of gerontology. Series A, Biological sciences and medical sciences.
[24] Ki-yong Kim,et al. Fructated apolipoprotein A-I showed severe structural modification and loss of beneficial functions in lipid-free and lipid-bound state with acceleration of atherosclerosis and senescence. , 2010, Biochemical and biophysical research communications.
[25] L. Grinberg,et al. Human apolipoprotein A-I binds amyloid-beta and prevents Abeta-induced neurotoxicity. , 2009, The international journal of biochemistry & cell biology.
[26] Kyung-Hyun Cho,et al. Synthesis of reconstituted high density lipoprotein (rHDL) containing apoA-I and apoC-III: the functional role of apoC-III in rHDL , 2009, Molecules and cells.
[27] Suzanne Craft,et al. The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. , 2009, Archives of neurology.
[28] A. Hill,et al. High density lipoproteins bind Abeta and apolipoprotein C-II amyloid fibrils. , 2006, Journal of lipid research.
[29] M. Hersberger,et al. High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease , 2004, Current opinion in lipidology.
[30] D. Russell,et al. Quantitation of two pathways for cholesterol excretion from the brain in normal mice and mice with neurodegeneration Published, JLR Papers in Press, June 16, 2003. DOI 10.1194/jlr.M300164-JLR200 , 2003, Journal of Lipid Research.
[31] J. Dietschy,et al. Cholesterol metabolism in the brain , 2001, Current opinion in lipidology.
[32] J. Lazo,et al. Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A beta aggregation and toxicity. , 2001, Biochemistry.
[33] A. Jonas,et al. A key point mutation (V156E) affects the structure and functions of human apolipoprotein A-I. , 2000, The Journal of biological chemistry.
[34] G. Siest,et al. Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer’s disease☆ , 2000, Neurobiology of Aging.
[35] A. Kumar,et al. Alzheimer's amyloid beta interaction with normal human plasma high density lipoprotein: association with apolipoprotein and lipids. , 1998, Clinica chimica acta; international journal of clinical chemistry.
[36] J. Thome,et al. Advanced glycation endproducts in ageing and Alzheimer's disease , 1997, Brain Research Reviews.
[37] B. Shilton,et al. Role of fructose in glycation and cross-linking of proteins. , 1988, Biochemistry.
[38] P. Matsudaira,et al. Sequence from picomole quantities of proteins electroblotted onto polyvinylidene difluoride membranes. , 1987, The Journal of biological chemistry.
[39] J. B. Massey,et al. Kinetics of lipid--protein interactions: effect of cholesterol on the association of human plasma high-density apolipoprotein A-I with L-alpha-dimyristoylphosphatidylcholine. , 1979, Biochemistry.
[40] N. Tolbert,et al. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. , 1978, Analytical biochemistry.
[41] Y H Chen,et al. Determination of the secondary structures of proteins by circular dichroism and optical rotatory dispersion. , 1972, Biochemistry.
[42] M. S. Blois,et al. Antioxidant Determinations by the Use of a Stable Free Radical , 1958, Nature.
[43] R. Havel,et al. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. , 1955, The Journal of clinical investigation.
[44] Yuan-Han Yang,et al. Effect of Advanced Glycation End Products on the Progression of Alzheimer's Disease. , 2019, Journal of Alzheimer's disease : JAD.
[45] M. Pai,et al. Apolipoprotein C-III is an amyloid-β-binding protein and an early marker for Alzheimer's disease. , 2014, Journal of Alzheimer's disease : JAD.
[46] H. Brewer,et al. Isolation and characterization of apolipoproteins A-I, A-II, and A-IV. , 1986, Methods in enzymology.